医学
髓系白血病
危险系数
造血干细胞移植
内科学
移植
回顾性队列研究
髓样肉瘤
比例危险模型
肿瘤科
髓样
胃肠病学
外科
置信区间
作者
Patrice Chevallier,Mohamad Mohty,Bruno Lioure,Gérard Michel,Nathalie Contentin,Éric Deconinck,Pierre Bordigoni,Jean‐Paul Vernant,Mathilde Hunault,Stéphane Vigouroux,Didier Blaise,Reza Tabrizi,Agnès Buzyn,Gèrard Socié,Mauricette Michallet,Christelle Volteau,Jean‐Luc Harousseau
标识
DOI:10.1200/jco.2007.15.6315
摘要
This retrospective multicenter study assessed the outcome of 51 patients with myeloid sarcoma (MS) who underwent allogeneic hematopoietic stem-cell transplantation (alloHSCT).Most patients had MS presenting in conjunction with acute myeloid leukemia (AML) or after AML. Six patients had isolated MS. The median time between diagnosis and alloHSCT was 8 months (range, 2.8 to 67). Forty patients were in complete remission (CR) at time of alloHSCT.With a median follow-up of 33 (range, 1 to 182) months, the Kaplan-Meier estimates of overall survival (OS) and disease-free survival were 47% (95% CI, 33% to 61%) and 36% (95% CI, 24% to 50%) at 5 years. Twenty patients (39%) relapsed at a median of 204 (range, 35 to 1151) days after alloHSCT, with relapse being the major cause of death. In a Cox multivariate analysis, age > or = 15 years and remission status at time of alloHSCT (CR v other) were associated with improved OS (hazard ratio [HR], 0.27; 95% CI, 0.12 to 0.65; P = .003; and HR, 0.22; 95% CI, 0.08 to 0.57; P = .002, respectively).We conclude that first-line alloHSCT performed early in the course of MS is a valid therapeutic option.
科研通智能强力驱动
Strongly Powered by AbleSci AI